ProfileGDS5678 / 1426258_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 95% 93% 92% 96% 93% 94% 95% 92% 93% 93% 93% 93% 94% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.8900493
GSM967853U87-EV human glioblastoma xenograft - Control 28.4404195
GSM967854U87-EV human glioblastoma xenograft - Control 37.8669493
GSM967855U87-EV human glioblastoma xenograft - Control 47.8480492
GSM967856U87-EV human glioblastoma xenograft - Control 58.7971496
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5357493
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9716494
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5603495
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.4853692
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.8196693
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.8090493
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.0060593
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.9318693
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.2579594